Harrabi Semi B, Koerber Stefan A, Adeberg Sebastian, Katayama Sonja, Herfarth Klaus, Debus Juergen, Sterzing Florian
Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Rep Pract Oncol Radiother. 2017 Sep-Oct;22(5):402-407. doi: 10.1016/j.rpor.2017.07.006. Epub 2017 Aug 11.
Malignant pleural mesothelioma (MPM) is a rare and aggressive disease that poses a treatment challenge in spite of recent technical developments. The aim of this retrospective analysis is to assess the feasibility of administering intensity-modulated radiotherapy (IMRT) to the pleural cavity using helical tomotherapy in patients who had undergone pleurectomy/decortication (P/D) and also the resulting toxicity levels.
Ten patients who had MPM and had undergone P/D were treated with pleural cavity irradiation that included a median dose of 52.2 Gy using helical tomotherapy. The median age of the patients was 53 years (31-74). In addition to clinical and diagnostic findings from regular follow-up examinations, we evaluated the dose distribution for other organs at risk to assess treatment in relation to toxicity, with special regard for the underlying intact lung.
The mean lung dose on the treatment site was 32.8 Gy (±6.8). The V was 71.7% (±17.2). No treatment-related toxicity that exceeded grade III according to common toxicity criteria (CTC) was observed. Median progression-free survival (PFS) was 13 months with a median overall survival (OAS) of 19 months.
The findings of this analysis provide data indicating that sparing the underlying lung in patients with MPM after P/D is not only feasible with helical tomotherapy, but that this treatment also causes reasonably few side effects.
恶性胸膜间皮瘤(MPM)是一种罕见且侵袭性强的疾病,尽管近年来技术有所发展,但仍面临治疗挑战。本回顾性分析的目的是评估在接受胸膜剥脱术/去皮质术(P/D)的患者中,使用螺旋断层放疗对胸腔进行调强放疗(IMRT)的可行性以及由此产生的毒性水平。
10例患有MPM且接受过P/D的患者接受了胸腔照射,使用螺旋断层放疗,中位剂量为52.2 Gy。患者的中位年龄为53岁(31 - 74岁)。除了定期随访检查的临床和诊断结果外,我们还评估了其他危及器官的剂量分布,以评估与毒性相关的治疗情况,特别关注潜在的完整肺脏。
治疗部位的平均肺剂量为32.8 Gy(±6.8)。V为71.7%(±17.2)。根据常见毒性标准(CTC),未观察到超过III级的与治疗相关的毒性。中位无进展生存期(PFS)为13个月,中位总生存期(OAS)为19个月。
本分析结果提供的数据表明,对于P/D术后的MPM患者,使用螺旋断层放疗保护潜在的肺脏不仅可行,而且这种治疗引起的副作用也相对较少。